HPS-200 - Pharmaceutical care pathway for endocrine therapy of breast cancer

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-200
• By: LI, Guohui
• Co-author(s): Dr Yanting Wang (Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)
  Prof. Guohui Li (Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)
  
• Abstract:

  Introduction: Endocrine therapy is one of the main treatments for hormone receptor-positive (HR+) breast cancer patients. There are many endocrine therapy-related drugs for HR+/human epidermal growth factor 2-negative (HER-2) breast cancer patients, which can be classified into at least 7 types according to mechanisms of action, such as selective..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login